Evidence map›Paper›PMID 35000210›Full record

ArticleAllergy2022

Serum periostin among infants with severe bronchiolitis and risk of developing asthma: A prospective multicenter cohort study.

Makiko Nanishi, Michimasa Fujiogi, Robert J Freishtat, Claire E Hoptay, Cindy S Bauer, Michelle D Stevenson, Carlos A Camargo, Kohei Hasegawa

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Periostin in Bronchiolitis Obliterans Syndrome after Lung Transplant.International journal of molecular sciences · 2024
    Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Makiko NanishiDepartment of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-0773-0412
Michimasa FujiogiDepartment of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4179-3612
Robert J FreishtatDepartment of Genomics and Precision Medicine, George Washington University, Washington, District of Columbia, USA.
Claire E HoptayChildren's Research Institute, Children's National Hospital, Washington, District of Columbia, USA.
Cindy S BauerDivision of Allergy and Immunology, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Michelle D StevensonDepartment of Pediatrics, Emergency Medicine, Norton Children's Hospital, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Carlos A CamargoDepartment of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kohei HasegawaDepartment of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard University · USChildren's National · USPhoenix Children's Hospital · USUniversity of Louisville · US

Funding

Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUH3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARLOS ARTURO CAMARGO · 2018 to 2026
$12.1M
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohortR01AI127507 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO, FREISHTAT, ROBERT J · 2017 to 2021
$8.0M
Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUG3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2016 to 2024
$6.8M
Airway dual-transcriptomics in bronchiolitis and risk of asthma: MARC-35 cohortR01AI137091 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.3M
Airway metagenome & metabolome in bronchiolitis and risk of asthma: MARC-35 cohortR01AI134940 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.0M
Infant blood epigenome and risks of IgE sensitization, obesity, and asthma: MARC-35/43 cohortsR01AI148338 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI CAMARGO, CARLOS ARTURO, LIANG, LIMING · 2020 to 2023
$2.5M
NIAID NIH HHS R01 AI127507NIAID NIH HHS R01 AI134940NIAID NIH HHS R01 AI137091NIAID NIH HHS R01 AI148338NIH HHS UG3 OD023253NIH HHS UH3 OD023253
6 · The paper itself

Abstract

backgroundInfants hospitalized for bronchiolitis (severe bronchiolitis) are at high risk for developing childhood asthma. However, the pathobiological link between these conditions remains unclear. We examined the longitudinal relationship of periostin (an extracellular matrix protein upregulated in response to type 2 inflammation) during bronchiolitis with the subsequent development of asthma.

methodsIn a 17-center prospective cohort study of infants (aged <1 year) with severe bronchiolitis, we measured the serum periostin level at hospitalization and grouped infants into 3 groups: low, intermediate, and high levels. We examined their association with asthma development by age 6 years and investigated effect modification by allergic predisposition (eg, infant's IgE sensitization).

resultsThe analytic cohort consists of 847 infants with severe bronchiolitis (median age, 3 months). Overall, 28% developed asthma by age 6 years. In the multivariable model adjusting for nine patient-level factors, compared to the low periostin group, the asthma risk was significantly higher among infants in the intermediate group (23% vs. 32%, OR 1.68, 95%CI 1.12-2.51, p = .01) and non-significantly higher in the high-level group (28%, OR 1.29, 95%CI 0.86-1.95, p = .22). In the stratified analysis, infants with IgE sensitization had a significantly higher risk for developing asthma (intermediate group, OR 4.76, 95%CI 1.70-13.3, p = .002; high group, OR 3.19, 95%CI 1.08-9.36, p = .04). By contrast, infants without IgE sensitization did not have a significantly higher risk (p > .15).

conclusionsIn infants with severe bronchiolitis, serum periostin level at bronchiolitis hospitalization was associated with asthma risk by age 6 years, particularly among infants with an allergic predisposition.

Indexed as

AsthmaBronchiolitisHypersensitivityChildCohort StudiesHumansImmunoglobulin EInfantProspective StudiesRisk FactorsImmunoglobulin Eallergic predispositionasthmabronchiolitischildrenperiostin

Identifiers

PMID35000210
PMCPMC9247040
OpenAlexW4206678311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.